Compare · IVVD vs VIR
IVVD vs VIR
Side-by-side comparison of Invivyd Inc. (IVVD) and Vir Biotechnology Inc. (VIR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IVVD and VIR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- VIR is the larger of the two at $2.25B, about 12.6x IVVD ($178.2M).
- VIR has been more active in the news (16 items in the past 4 weeks vs 2 for IVVD).
- VIR has more recent analyst coverage (19 ratings vs 7 for IVVD).
- Company
- Invivyd Inc.
- Vir Biotechnology Inc.
- Price
- -
- -
- Market cap
- $178.2M
- $2.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 2
- 16
- Recent ratings
- 7
- 19
Vir Biotechnology Inc.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Latest IVVD
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
- Invivyd to Participate in Upcoming September Investor Conferences
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sheffield Ian
- SEC Form 3 filed by new insider Sheffield Ian
Latest VIR
- SEC Form SCHEDULE 13G filed by Vir Biotechnology Inc.
- Vir Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
- Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
- Amendment: SEC Form SCHEDULE 13D/A filed by Vir Biotechnology Inc.
- Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
- SEC Form 10-Q filed by Vir Biotechnology Inc.
- Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- EVP, General Counsel, Corp Sec De Verneuil Vanina sold $41,939 worth of Common Stock (3,750 units at $11.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 110,193 units (SEC Form 4) (for withholding tax)